Journal of Clinical Oncology

Oxaliplatin Dosing and Toxicity: A Cautionary Perspective on Efficacy

M Merve Kuday Özkan (Merve Kuday Özkan, MD, Department of Medical Oncology, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey; Seher Kaya, MD, Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, Turkey; and Ömer Dizdar, MD, Department of Medical Oncology, Hacettepe University, Ankara, Turkey) S Seher Kaya (Merve Kuday Özkan, MD, Department of Medical Oncology, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey; Seher Kaya, MD, Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, Turkey; and Ömer Dizdar, MD, Department of Medical Oncology, Hacettepe University, Ankara, Turkey) O Omer Dizdar
View Original
APA MLA Chicago BibTeX RIS

Article Details

Volume / Issue Vol. 43, Issue 34
Published December 01, 2025
Pages 3686-3686
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins
ISSN: 0732-183X Health Sciences

Authors (3)

M

Merve Kuday Özkan

Merve Kuday Özkan, MD, Department of Medical Oncology, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey; Seher Kaya, MD, Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, Turkey; and Ömer Dizdar, MD, Department of Medical Oncology, Hacettepe University, Ankara, Turkey

S

Seher Kaya

Merve Kuday Özkan, MD, Department of Medical Oncology, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey; Seher Kaya, MD, Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, Turkey; and Ömer Dizdar, MD, Department of Medical Oncology, Hacettepe University, Ankara, Turkey

O

Omer Dizdar

Related Articles from this Journal

Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Ismaela Anna Vascotto, Filippo Antonica et al. Aug 2026 10.1200/jco-26-00658

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Samer A. Srour, Jad Chahoud et al. Aug 2026 10.1200/jco-26-00388

Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection

Risako Komata, Kenju Ando et al. Aug 2026 10.1200/jco-26-00140

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)

Ghayas C. Issa, Branko Cuglievan et al. Aug 2026 10.1200/jco-26-01743

Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Irbaz Bin Riaz, R. Bryan Rumble et al. Aug 2026 10.1200/jco-26-01001